Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Daiichi Sankyo To Begin Flu Vaccine Supply After Month-long Delay

This article was originally published in PharmAsia News

Executive Summary

Daiichi Sankyo vaccine joint venture Kitasato Daiichi Sankyo Vaccine will begin supplying flu vaccines starting at the end of October

Daiichi Sankyo vaccine joint venture Kitasato Daiichi Sankyo Vaccine will begin supplying flu vaccines starting at the end of October.

The supply, originally scheduled for mid-September, was postponed Sept. 22 due to the contamination of avian renovirus, which was found to have affected 2.36 million doses, more than half of a total projected supply of 4.78 million. The first supply will be 1.2 million doses, which were confirmed to have cleared Japanese health standards, according to the company. The second supply of 1.22 million is scheduled between November and December. Daiichi will produce an additional 1.2 million doses to be shipped at the beginning of the next year. (Click here for more - Japanese language)

"Kitasato Daiichi Sankyo Vaccine To Start Supply This Month" - CB News (10/17/2011)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC076484

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel